No Fanfare For US Approval Of Sanofi's GLP-1 Adlyxin
Sanofi has secured US approval for its a once-daily mealtime GLP-1 injection Adlyxin (lixisenatide) as an adjunct to diet and exercise for the treatment of adults with type 2 diabetes, but as the sixth GLP-1 product to enter this market the drug is unlikely to gain a strong foothold.
You may also be interested in...
"A somewhat challenging quarter," was how Sanofi CEO Olivier Brandicourt described the second three months of 2016, but analysts say there were no surprises in the downward trajectory of Sanofi's fortunes. There was also little news on Sanofi's pursuit of Medivation.
A selection of articles you might have missed from April 2022, including exclusive interviews, an in depth look at the impact of COVID-19 on clinical trial trends, and the latest Rising Leaders series.
Rising Leader Yolanda Tibbe, Novartis’s head of new commercial partnerships in Germany, talks about transformation at the Swiss big pharma and how to put ‘patients as customers’ thinking into action.